[{"data":1,"prerenderedAt":154},["ShallowReactive",2],{"drug-eptinezumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":59,"warnings":69,"renal":77,"monitoring":78,"interactions":79,"review":80,"examples":83,"atc":89,"iran":91,"usApproval":98,"links":104,"populations":119},"eptinezumab",1,{"fa":7,"en":8},"اپتینزوماب","Eptinezumab","nervous-system",{"fa":11,"en":12},"آنتی‌بادی ضد CGRP (وریدی)","Anti-CGRP monoclonal antibody (IV)",[14],{"name":15,"market":16},"Vyepti","US",[18,19,7],"vyepti","وایپتی",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"vial-100","injection","iv","100 mg\u002FmL vial",{"amount":27,"unit":28,"perVolumeMl":5},100,"mg",[16],[31],{"source":32,"section":33},"fda-vyepti","3",[35],{"id":24,"disease":36,"label":37,"population":40,"type":44,"unit":28,"dose":45,"refs":47,"durationDays":50,"notes":51},"migraine-prophylaxis",{"fa":38,"en":39},"پیشگیری میگرن بزرگسال — ۱۰۰ mg انفوزیون وریدی ۳۰ دقیقه هر ۳ ماه (برخی ۳۰۰ mg)","Migraine prevention, adults — 100 mg IV infusion over 30 min every 3 months (some 300 mg)",{"minAge":41},{"value":42,"unit":43},18,"year","fixed",{"perDose":27,"perDoseMax":46,"dosesPerDay":5},300,[48],{"source":32,"section":49},"2.1",{"min":5,"max":5},[52],{"text":53,"refs":56},{"fa":54,"en":55},"فقط در ۱۰۰ mL سرم نرمال سالین رقیق شود.","Dilute only in 100 mL 0.9% sodium chloride.",[57],{"source":32,"section":58},"2.2",[60],{"id":61,"severity":62,"text":63,"refs":66},"hyper","block",{"fa":64,"en":65},"حساسیت جدی به اپتینزوماب.","Serious hypersensitivity to eptinezumab.",[67],{"source":32,"section":68},"4",[70],{"text":71,"refs":74},{"fa":72,"en":73},"واکنش حساسیتی؛ یبوست با عوارض جدی؛ فشار خون بالا؛ پدیده رینود.","Hypersensitivity; constipation with serious complications; hypertension; Raynaud phenomenon.",[75],{"source":32,"section":76},"5",[],[],[],{"status":81,"reviewer":82,"date":82},"unverified",null,[84],{"regimen":24,"formulation":22,"input":85,"expect":88},{"ageYears":86,"weightKg":87},35,65,{"perDose":27,"mlPerDose":5,"upperPerDose":46},[90],"N02CD05",{"status":92,"refs":93},"not-found",[94],{"source":95,"section":96,"url":97},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Eptinezumab",{"kind":99,"refs":100,"id":103},"BLA",[101],{"source":32,"section":102},"SPL approval \u002F marketing category","BLA761119",[105,108,112,116],{"kind":106,"url":107,"label":103},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=761119",{"kind":109,"url":110,"label":111},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=79065861-6aa5-4d1f-829f-3a6471286b36","FDA Vyepti",{"kind":113,"url":114,"label":115},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa620022.html","Eptinezumab-jjmr Injection",{"kind":117,"url":118,"label":90},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N02CD05",{"pregnancy":120,"lactation":129,"pediatric":137,"geriatric":146},{"level":121,"text":122,"quote":125,"refs":126},"caution",{"fa":123,"en":124},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on developmental risks associated with the use of VYEPTI in pregnant women.",[127],{"source":32,"section":128},"8.1",{"level":121,"text":130,"quote":133,"refs":134},{"fa":131,"en":132},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production.",[135],{"source":32,"section":136},"8.2",{"level":138,"text":139,"quote":142,"refs":143},"not-established",{"fa":140,"en":141},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[144],{"source":32,"section":145},"8.4",{"level":121,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.",[152],{"source":32,"section":153},"8.5",1792191541880]